This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2- 391 in patients with bone-metastatic, castrate- resistant prostate cancer (CRPC) who have not had prior chemotherapy.
We care about your feedback. Let us know how we can improve your CancerCompass experience.